Tempus Priority Study: A Pan-tumor Observational Study

Study Purpose

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Solid or hematologic malignancy. 2. Willing and able to provide informed consent where required. 3. Has received or will receive genomic profiling.

Exclusion Criteria:

1. Individuals without the capacity to consent. 2. Prisoners at the time of enrollment.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05179824
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Tempus AI
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Kristiyana Kaneva, MD, MS, MBA
Principal Investigator Affiliation Tempus AI, Inc.
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Additional Details

The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.

Arms & Interventions

Arms

: Group 1: Standard of Care (SOC) CGP

This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.

Interventions

Other: - Observation

No Intervention

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Providence Medical Foundation, Napa, California

Status

Withdrawn

Address

Providence Medical Foundation

Napa, California, 94558

Community Health, Indianapolis, Indiana

Status

Withdrawn

Address

Community Health

Indianapolis, Indiana, 46250

Pontchartrain Cancer Center, Covington, Louisiana

Status

Withdrawn

Address

Pontchartrain Cancer Center

Covington, Louisiana, 70433

Central Care Cancer Center, Bolivar, Missouri

Status

Withdrawn

Address

Central Care Cancer Center

Bolivar, Missouri, 65613

Belleville, New Jersey

Status

Withdrawn

Address

New Jersey Cancer Center and Blood Disorders, New Jersey Cancer Care

Belleville, New Jersey, 07109

New York, New York

Status

Withdrawn

Address

Perlmutter Cancer Center, NYU Langone Health

New York, New York, 10016

Cincinnati, Ohio

Status

Withdrawn

Address

TriHealth Cancer Institute- Good Samaritan Hospital

Cincinnati, Ohio, 45220

OhioHealth, Columbus, Ohio

Status

Withdrawn

Address

OhioHealth

Columbus, Ohio, 43214

Tulsa, Oklahoma

Status

Withdrawn

Address

Oklahama Cancer Specialists and Research Institute

Tulsa, Oklahoma, 74146

Cancer Care Associates of York, York, Pennsylvania

Status

Withdrawn

Address

Cancer Care Associates of York

York, Pennsylvania, 17403

UT Southwestern, Dallas, Texas

Status

Recruiting

Address

UT Southwestern

Dallas, Texas, 75390

Site Contact

Donna Mitchell

prioritystudy@tempus.com

214-645-8789

Baylor College of Medicine, Houston, Texas

Status

Recruiting

Address

Baylor College of Medicine

Houston, Texas, 77030

Site Contact

Merin Thomas

merint@bcm.edu

713-798-7291

Stay Informed & Connected